cIAP-2 Inhibitor

SM-122 is a Smac mimetic and an IAP inhibitor. SM-122 binds the XIAP BIR3, cIAP‑1 BIR3, and cIAP‑2 BIR3 domains with K_i values of 26 nM, 1.0 nM, and 1.8 nM, respectively. SM‑122 triggers intracellular degradation of cIAP‑1 and cIAP‑2 proteins, relieving IAP-mediated inhibition of caspases. SM-122 inhibits cancer cell growth and induces apoptosis and caspase-dependent cell death in tumor cells. SM-122 can be used for research on cancers such as breast cancer and ovarian cancer.

Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.

FL113 is a racemate of FL118 (HY-12486). FL113 is less effective than FL118 in inhibiting the expression of Survivin, Mcl-1, XIAP, and cIAP2. FL113 exhibits weaker antitumor activity than FL118 in colon tumor xenograft models. FL113 can be used for research on colon cancer and head and neck cancer.

Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.